SWX:IDIABiotechs
Assessing Idorsia (SWX:IDIA) Valuation After Lucerastat Phase 3 Fabry Disease Results
Why the lucerastat data matters for Idorsia shares
Idorsia (SWX:IDIA) just put fresh Phase 3 and long term lucerastat data for Fabry disease into the public domain, with kidney and cardiac outcomes now in focus after the study missed its primary pain endpoint.
For you as a shareholder or potential investor, this shifts attention to how lucerastat might fit into Idorsia's broader rare disease pipeline, future regulatory discussions, and the perceived value of its R&D portfolio.
See our latest...